Involved in many disease pathologies, DUBs are attractive therapeutic targets
World-leading DUB platform translating scientific advances into transformative therapies
First-in-class small molecule DUB inhibitors developed in-house and with partners
Multiple in-house DUB inhibitor programs in the clinic or approaching clinical development
Mission Therapeutics is determined to make a positive impact on the lives of patients suffering from serious diseases including acute kidney injury (AKI), rare mitochondria diseases, neurodegeneration, and fibrosis by developing first-in-class therapeutics that inhibit disease-associated deubiquitylating enzymes (DUBs).
To hear our CEO discuss our technology, programs, recent progress and strategy, watch our Corporate Presentation.
Mission Therapeutics to Present at the Targeted Protein Degradation Europe Conference 2023
Presentation at 9am Thursday, March 30th 2023